Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Mescaline/Adolescents

Mescaline for Adolescents

5 papers and 0 clinical trials exploring mescaline as a treatment for adolescents.

CompoundPhenethylamine

Mescaline

A naturally occurring phenethylamine psychedelic found in certain cacti, investigated for its role in religious practice and psychiatric research.

Full Mescaline profile
Indication1 in 7 adolescents lives with a mental disorder

Adolescents

Adolescents are a developing-brain, vulnerable population that the modern psychedelic field has mostly studied from the outside: almost all psychedelic trials enrol adults, not minors. The one mature clinical thread in under-18s is ketamine and esketamine for depression and acute suicidality, where benefits are real but modest and often matched by active-placebo arms. For classic psychedelics like psilocybin, LSD and MDMA there is essentially no controlled evidence in adolescents, and the developing brain raises safety questions that adult data cannot answer.

Full Adolescents profile

Academic Research

5 papers
Open Accessindividual

Psilocybin-assisted therapy and HIV-related shame

In a pilot clinical trial (N = 12), psilocybin-assisted group therapy produced a large, statistically significant reduction in HIV-related shame from baseline to three-month follow-up. However, two participants experienced a paradoxical worsening of sexual abuse–related shame, highlighting potential risks for trauma-exposed patients.

Published
August 2, 2024
Journal
Scientific Reports
Authors
Mehtani, N. J., Johnson, M. O., Hendricks, P. S., Mitchell, J., Anderson, B. T.
Open Accessmeta

Drug-drug interactions involving classic psychedelics: A systematic review

This systematic review of 52 human studies summarises drug–drug interactions between classic psychedelics (LSD, psilocybin, mescaline, DMT, 5‑MeO‑DMT) and various psychotropic and recreational drugs, finding heterogeneous outcomes — attenuated, potentiated or unchanged effects — with few serious adverse events reported beyond isolated case reports. The paper provides a comprehensive synthesis of clinical evidence and discusses potential molecular mechanisms underlying these interactions.

Published
November 20, 2023
Journal
Journal of Psychopharmacology
Authors
Halman, A., Kong, G., Sarris, J., Perkins, D.
Open Accessindividual

Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users-A National Survey Study

Analysing nationally representative YRBSS data from 2001–2019 (125,550 students), 8.4% of adolescents reported lifetime hallucinogen use, declining from 13.3% to 7.0% over the period. Hallucinogen users had significantly higher odds of feeling sad or hopeless, suicidal ideation and planning, and markedly greater co‑occurring use of alcohol, tobacco, cannabis and other illicit drugs.

Published
December 5, 2022
Journal
Children
Authors
Desai, S., Jain, V., Xavier, S., Du, W.
Open Accessmeta

Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine

This review (2018) examines the synthesis of MDMA as well as its pharmacology, metabolism, adverse effects, and potential use in medicine.

Published
July 12, 2018
Journal
ACS Chemical Neuroscience
Authors
Dunlap, L. E., Andrews, A. M.
Paywallindividual

Autistic Schizophrenic Children: An Experiment in the Use of D-Lysergic Acid Diethyladmide (LSD-25)

This early study (1962; n=12) with LSD (50-200µg) on children with autism (ASD) and schizophrenia, of which 7 were mute, showed that LSD elicited large psychological changes in this population, but no change in muteness. Procedures for consent were different/non-existent at that time.

Published
March 1, 1962
Journal
JAMA Psychiatry
Authors
Freedman, A. M.

Clinical Trials

0 trials

No clinical trials have been tagged with both Mescaline and Adolescents yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all Mescaline papers Search all Adolescents trials Full Mescaline profile Full Adolescents profile